Or that the one early randomized trial that clearly showed the benefit was sabotaged and therefore could not be solely relied on for BT designation.
It doesn't have to be that hard. Bottom line is the sabotage allowed all the other BPs to get ahead and get their I/O drugs out in the limelight before pphm could raise the bar needed in overall survival. Mission accomplished. PPHm delayed 3/4 years but maybe just maybe a little mitigation in the way of not underselling their science to Abbvie because their MOA was less clear.